featured
Early Treatment of COVID-19 With Anakinra Guided by Soluble Urokinase Plasminogen Receptor Plasma Levels
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Nat. Med. 2021 Sep 03;[EPub Ahead of Print], E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, K Tsiakos, A Fragkou, A Rapti, C Damoulari, M Fantoni, I Kalomenidis, G Chrysos, A Angheben, I Kainis, Z Alexiou, F Castelli, FS Serino, M Tsilika, P Bakakos, E Nicastri, V Tzavara, E Kostis, L Dagna, P Koufargyris, K Dimakou, S Savvanis, G Tzatzagou, M Chini, G Cavalli, M Bassetti, K Katrini, V Kotsis, G Tsoukalas, C Selmi, I Bliziotis, M Samarkos, M Doumas, S Ktena, A Masgala, I Papanikolaou, M Kosmidou, DM Myrodia, A Argyraki, CS Cardellino, K Koliakou, EI Katsigianni, V Rapti, E Giannitsioti, A Cingolani, S Micha, K Akinosoglou, O Liatsis-Douvitsas, S Symbardi, N Gatselis, M Mouktaroudi, G Ippolito, E Florou, A Kotsaki, MG Netea, J Eugen-Olsen, M Kyprianou, P Panagopoulos, GN Dalekos, EJ Giamarellos-BourboulisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.